Seek­ing a place among gi­ants in the on­colyt­ic virus field, lit­tle Cold Genesys bags $22M Se­ries C

A small biotech out of Cal­i­for­nia has re­fu­eled with $22 mil­lion for the next leg of its quest in on­colyt­ic im­munother­a­pies, a hot field that’s grabbed the at­ten­tion of ma­jor phar­ma play­ers keen to find the win­ning com­bo tech in the I/O 2.0 race.

Cold Genesys and its in­vestors for the Se­ries C are pret­ty much putting all their eggs in the CG0070 bas­ket. The com­pa­ny bought the drug, which had al­ready gone through Phase I, from BioSante Phar­ma­ceu­ti­cals back when it first got start­ed in 2010, with $95,000 up­front and a 20% stock own­er­ship. Fast for­ward nine years, CG0070 has been test­ed in more than 100 blad­der can­cer pa­tients in a Phase II as a monother­a­py, and is lined up for com­bi­na­tion tri­als with Mer­ck’s Keytru­da as well as oth­er check­point mod­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.